Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma

NCT06843967 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT06843967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06843967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 19, 2025
Completion date
August 19, 2028
Enrollment
54 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

dedifferentiated liposarcoma, liposarcoma, myxoid liposarcoma, myxoid pleomorphic liposarcoma, pleomorphic liposarcoma, round cell liposarcoma, unresectable dedifferentiated liposarcoma, unresectable liposarcoma, well differentiated liposarcoma